AstraZeneca's new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.

AstraZeneca said Monday its experimental pill lowered "bad" LDL cholesterol by 51%. The results showed promise against rival drugs from Merck and NewAmsterdam Pharma, but AstraZeneca stock fell.

An investigational PCSK9 inhibitor with a different mechanism from existing drugs in this class has been shown to safely and ...

AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes for a potential blockbuster that could be part of a powerful ...

In a Phase Ib trial, VERVE-102 showed it could lower bad cholesterol across doses, setting up an opt-in decision for Eli ...

31,066 people played the daily Crossword recently. Can you solve it faster than others?31,066 people played the daily Crossword recently. Can you solve it faster than others?

A unit of AstraZeneca Plc is facing a new antitrust suit claiming the company monopolized the market for a blood disorder ...

Subscribe here to receive future editions. The race to develop more convenient versions of drugs that lower cholesterol is heating up after AstraZeneca released encouraging new data on an ...